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1. Introduction 
Hemolytic anemias are a group of diseases characterized by a reduction in red blood cells 
(RBC) life span mainly caused by a deregulation in the hemoglobin formation. Among these 
diseases, Sickle Cell Disease (SCD) and Beta Thalassemia (Thal) are the most common 
disorders involved in the premature destruction of RBC. Understanding the molecular 
mechanisms involved in the outcome of these diseases as well as the metabolic pathways 
surrounding its onset constitutes a very useful approach to target treatment strategies for 
such diseases. In this chapter we will discuss the state-of-the-art aspects about this theme 
highlighting the importance of several point mutations in hemolytic anemia using  
thalassemia and sickle cell disease as examples. In addition, the molecular aspects involved 
in the Hereditary Persistence of Fetal Hemoglobin (HPFH), also an important disorder 
caused by point mutations and deletions, and its association with the severity of Thal and 
SCD will be also discussed. In this context lies the manifestation of better prognostic to 
patients having an increase in fetal hemoglobin and SCD or Thal concomitantly. Therefore 
a parallel discussion towards the advances currently described in the literature and 
associations of gene expression and different drugs that increase the production of fetal 
hemoglobin (HbF) are pointed out as a mechanism to improve the quality of life of SCD and 
Thal patients.  
2. The erythroid cell 
Erythroid proliferation is a precisely regulated process, in which hematopoietic stem cells 
(HSCs) differentiate into lineage-restricted erythroid progenitors through a process called 
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erythropoiesis. While in adult humans the process occurs basically in the bone marrow 
(BM), the primitive hematopoiesis occurs initially in the yolk sac (YS). (Fig. 01) The 
regulation of cellular proliferation, survival and differentiation is a strictly regulated process 
in all the producing cells and are stimulated by extracellular signaling molecules, 
particularly erythropoietin (EPO), a hormone synthesized by the kidney. This hormone 
functionally activates its receptor called EPOR on the surface of red blood cells (RBCs) 
precursor cells in the BM. The first cell line formed after this stimulus is known as Burst 
Forming Unit-Erythroid (BFU-E) (Hoffman et al. 2008).   
 
Fig. 1. Sites of hematopoesis during the human development. During the very first weeks of 
human development the hematopoiesis occurs in the yolk sac. After the first month, the 
hematopoietic site is switched to spleen and liver and after the seventh month all the 
hematopoiesis occurs in long bones. Following  the birth and during the adult life the 
hematopoesis site is in the axial skeleton. 
After the EPO stimulus, cells undergo several modifications that lead to the formation of 
RBCs. The first step occurs when the Burst forming unit erythroid cells (BFU-E) originates 
the colony-forming units erythroid (CFU-E), which differentiates to the first 
morphologically identifiable stage of the erythroid cells, the proerythroblasts. Successive 
modifications lead the cell to several transforming processes generating the basophilics 
erythroblasts, polychromatophilics erythroblasts, orthochromics erythroblasts. At this stage, 
the nucleus becomes picnotic and is extruded of the cell forming the reticulocyte. This cell 
presents a biconcave shape and contains residual remaining RNA. Reticulocytes are released 
into the blood and develop into mature erythrocytes within about two days (Fig. 02) 
(Hoffman et al. 2008; Tsiftsoglou et al. 2009). 
Under normal conditions, erythrocytes life span is about 120 days. After this time, the 
erythrocytes undergo several morphological changes, specially caused by reduction in its 
metabolic activity and the hemoglobin content oxidation (Ghaffari 2008). These cell 
alterations are ultimately recognized by mononuclear phagocyte system (MPS). The cells are 
then removed from bloodstream in that the majority of the cell components are recycled and 
used in the production of new cells. The MPS consists of phagocytic cells (macrophages and 
monocytes) residents in the liver and spleen which are the major organs responsible for 
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RBCs removal. An increase in RBCs destruction independent from the etiology results in a 
clinical disorder generally called anemia. This unbalanced destruction of the RBC 
population is the most important feature found in several hemolytic diseases like sickle cell 
disease and Thal that will be further discussed in detail later on in this chapter (Telen et al. 
1999; Hoffman et al. 2008). 
 
Fig. 2. Morphological changes during erythropoiesis in humans – After EPO stimulus the 
erythroid cell undergo several morphological changes that lead to the formation of mature 
erythrocytes. For details see the text. Figure was produced using Servier Medical Art, 
http://www.servier.co.uk/medical-art-gallery/SlideKit.asp?kit=18. 
3. The hemoglobin 
The main function of erythrocytes is the transport of oxygen from lung to peripheral tissues 
and carbon dioxide from them to the lung. This function is performed by the hemoglobin 
(Hb) molecule, a protein tetramer which comprises 95% of the whole protein content in 
RBC.  
Hemoglobin synthesis requires the coordinated production of different globin proteins 
combined with a non-protein heme group as a prosthetic group. Heme molecule consists of 
an iron (Fe) ion held in a heterocyclic ring, known as a porphyrin. The protoporphyrin 
present in erithrocytes is the protoporphyrin IX which is a complex structure of a tetrapyrole 
structure. This molecule comprises four pyrole rings having eight sites for side chain groups 
substituents at its periphery. The protoporphyrin IX can then be described as 1,3,5,8 methyl; 
2,4 vinyl; 6,7 propionic acid-porphiryn. The designation of protoporphiryn IX refers to the 
fact that from the 15 possible isomers of protoporphyrin, the ninith one that Hans Fischer 
(the pioneer in the chemical foundations of proptoprphyrin molecules) synthetized was 
exactly the same naturally occurring in the heme molecule. Therefore, the IX isomer is the 
only one found in nature (Greer et al. 2008).  
Iron is the site of oxygen binding when it is in the ferrous (Fe2+) oxidation state. The 
hemoglobin can be saturated with oxygen molecules (oxyhemoglobin), or desaturated 
without oxygen (deoxyhemoglobin). Two distinct globin chains are combined to form 
hemoglobin, the alpha and non-alpha (Fig. 3a). 
The alpha cluster located at chromosome 16 is responsible for the production of  and  
globin. On the other hand, the production of non-alpha chains occurs in the  cluster located 
at chromosome 11. In this latter cluster the , ,  and  globin are produced. (Fig. 3b) (Tang 
et al. 2008). 
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Fig. 3. Formation of hemoglobin during the human development – (A) Schematic 
representation of hemoglobin showing its molecules. (B) The hemoglobin is composed by 
the combination of two alpha and two non-alpha chains. The proteins are produced by the 
expression of several genes located in the  and  cluster at Chromosome 16 and 11 
respectively. 
The ontogeny of globin synthesis during development is complex and dynamic having 
different proteins being produced by different clusters. During the first weeks of 
embryogenesis the predominant globin chain synthetized by  cluster is the  globin. After 
this time, the globin chain produced by the  cluster is always represented by the  globin. 
However, the  cluster can produce several different globin proteins as shown  in Fig. 3. 
During the fetal period, the non-alpha globins produced are the  (2 - 6 weeks) and  (after 
the 6th week). After the birth, the  gene is silenced and the transcription of the  and  gene 
starts indefinitely. The most abundant globin occurring after the birth expressed by  cluster 
is the  globin that represents about 98% of non-alpha chains found in the mature 
erythrocyte The control mechanisms of the transcription modulation of globin genes are not 
completely understood. Some studies showed that the Locus Control Region (LCR) present 
in  cluster and the HS40 (Hypersensitive site 40) region in  cluster bend on the promoter 
of each gene enhancing its transcription. When these regions fold up in the subsequent 
promoter, the silencing of the preceding gene occurs with the consequent activation of 
transcription in the subsequent gene. The transcription factors involved in LCR and HS40 
movements remains unclear but some relevant aspects of this regulation module will be 
discussed later in this section. The combination of two  chains and two non- chains 
produces a complete hemoglobin molecule (Palstra et al. 2003; Hoffman et al. 2008).  
In humans, as for the expression of globin genes, the production of Hb is also 
ontogenetically regulated. Therefore, different types of hemoglobin are produced according 
to the developmental cell stage (i. e. embryonic, fetal and adult). Embryonic Hbs are 
produced early during hematopoiesis when erythropoiesis is predominantly in the yolk sac. 
The first hemoglobin produced in embryo is the gower 1 formed by the combination of two 
 globins and two  globins (22). The hemoglobin Gower 2 is then formed by the 
combination of two  and two  globin (22). The Portland hemoglobin is the third class of 
globins produced in embryos as a result of the association of two  and two  globin (22). 
During the fetal period the first hemoglobin switching takes place when the  globin is 
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combined with  globin (22), producing the fetal hemoglobin (HbF). In this period, the 
hemoglobin is synthesized in the liver. During the first six weeks after the birth, occurs the 
second hemoglobin switching. At this stage the  globin synthesis is drastically decreased 
and the production of  globin starts. The combination of  and the newly  globin 
produced results in the major hemoglobin counterpart found during the adult life which is 
called HbA1 (22). There is also another adult normal hemoglobin formed by the 
combination of  and  globins the HbA2 (22), that represents 1.5-3.5%. The Fig. 4 shows 
the ontogenetic production of hemoglobin depicting the sites of production and the time of 
development where the different globin chains peaks in concentration (Fig. 04) 
(Stamatoyannopoulos 2005). 
 
Fig. 4. The production of different types of hemoglobins during human development – 
During human development different types of hemoglobin are produced.  In  the embryonic 
phase de Hb Gower 1 and 2 and also Hb Portland are produced. In the fetal phase the 
combination of  and  proteins produced the HbF. After the birth, two hemoglobins are 
produced, the HbA2 that represents about 1.5- 3.5% of total hemoglobin in adult blood and 
the HbA that represents 95 - 98% of hemoglobin.  
3.1 The genetic regulation of globin genes 
As discussed earlier, the genetic control of hemoglobin production is not completely 
understood, however several studies showed that globin genes can be expressed and 
repressed upon the regulation of several transcription factor that can interact with the globin 
gene promoters. As mentioned before, in the  globin cluster, the LCR can interact with the 
different globin genes in this cluster forming the different types of hemoglobin. This region 
is comprised of hypersensitive sites, which are DNA stretches with marked sensitivity to in 
vitro DNAse treatment. The precise function of LCR is not still completely clear. Several 
studies have shown that it acts as a “super-enhancer” DNA sequence that is thought to  
interact with each globin gene in the cluster by the interactions with several transcription 
factors. There are some other important regions surrounding the globin genes that are 
probably involved in its own transcription. One of these regions is a sequence spanning -80 
and -120 bp upstream the start codon called the TATA and CAT box, respectively. These 
regulatory regions bind to and interacts with RNA polymerase in the beginning of globin 
gene transcription. Also of seminal importance is the region located at 3’ region of the 
transcription start site, called as the GATA binding sequence. In such region, a transcription 
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factors called GATA, a zinc-finger family of transcription factors (GATA 1-6), interacts with 
DNA and can both activate and repress target genes involved in erythroid development 
(Strauss et al. 1992; Strauss et al. 1992; Cao et al. 2011).   
Specially in - and -globin loci, several binding sites for this family are found, suggesting 
an important role of these proteins in the regulation of these genes. The same motif is also 
found in the promoters of several genes that are also regulated during the erythroid 
development. GATA1 is the main member of these family involved in erythroid cell 
maturation in vivo. Its expression is essential for the formation of erythroid definitive lineage 
and several studies showed that erythroid Gata1-null cells can not mature beyond the 
proerythroblast stage. GATA1 seems to be also involved in the switching of the fetal to adult 
hemoglobin. Mutation in GATA1 gene has been described as involved in congenital 
erythropoietic porphyria and elevated levels of HbF. However the exact mechanism that 
links this gene to the elevation of  globin is still not completely clear (Weiss et al. 1994; 
Blobel et al. 1995; Weiss et al. 1995; Blobel et al. 1996; Weiss et al. 1997; Blobel et al. 1998). 
As mentioned before, these DNA sequences are well recognized as sites of bona fide globin 
gene expression regulation. The presence of mutations in such regions leads to a 
deregulation in the expression of globin genes causing either interruption or a decreased 
expression of such genes. 
Besides this, regulation involving the gene transcription licensing, several other genetic 
factors have been described up to now as involved in the globin gene regulation. The 
BCL11A gene, as the GATA family is a zinc-finger protein, firstly identified as a potentially 
important factor in globin regulation and as a master regulator in the switch of the fetal to 
adult hemoglobin in humans. This gene is under the transcriptional regulation of a 
transcription factor known as KLF1 (Kruppel-like factor). KLF1 binds to a CACCC motif and 
this association is also strictly correlated to  to -globin gene switching. Mutation in this 
binding motif is associated with human Thal and Hereditary Persistence of Fetal 
Hemoglobin that will be discussed later on (Sankaran et al. 2008; Xu et al. 2010). 
Another important set of genes involved in the erythroid terminal differentiation is SOX6 
and ALAS2. SOX6 is a transcription factor expressed in several human tissues. Specifically 
in erythroid cells, it has been reported that SOX6 expression is crucial to promote erythroid 
final maturation, since an increased number of nucleated and immature red cells are 
observed in blood stream when this gene is deleted in mouse. ALAS2 is the enzyme 
catalysing the first and regulatory step of heme synthesis. Its expression is restricted to 
erythroid precursor cells. Therefore, reported mutations in ALAS2 have been linked to 
ineffective erythropoiesis and associated to X-linked sideroblastic anaemia (Ducamp et al. 
2010; Wilber et al. 2011). 
3.2 Hemolytic anemia 
Despite many studies focusing on the understanding of the complete regulation of 
hemoglobin formation highlighted in the previous section, many aspects of this regulation 
are still to be addressed. Deregulation of hemoglobin formation is involved in the reduction 
of red blood cells leading to a important disorder called hemolytic anemia After the normal 
life span of about 120 days, the red blood cells need to be removed from the circulation. 
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Spleen and liver are the most important tissues responsible for the destruction and recycling 
of red blood cells components. In normal conditions, the destruction of these cells is 
balanced with their production in the bone marrow and the number of circulating red blood 
cells is physiologically maintained (Hoffman et al. 2008).   
An unbalanced rate of destruction and production of RBC can increase or reduce the 
population of circulating cells. The increase of these cells is denominated policytemia and 
this clinical condition is present in several proliferative disorders. On the other hand, the 
reduction of RBC number consists of anemia and can be developed by several reasons, 
including some erythroid diseases including sickle cell disease and Thal. In these cases, the 
anemia is called hemolytic because the established condition is caused by an increase in 
hemolysis of the RBC. 
The anemia is most often diagnosed through hematological tests in which a decrease in 
hemoglobin concentration and in RBC cell count are detected. Despite the laboratory 
diagnosis, the clinical history and physical examination can provide important clues about the 
presence of hemolysis and its underlying cause. The patient may complain of dyspnea or 
fatigue (caused by anemia). Dark urine and, occasionally, back pain may be reported by 
patients with intravascular hemolysis. The skin may appear jaundiced or pale. A resting 
tachycardia with a flow murmur may be present if the anemia is pronounced. Leg ulcers occur 
in some chronic hemolytic states, such as sickle cell anemia. Hepatosplenomegaly suggest an 
abnormal RBC destruction caused by accentuated hemolysis (Hoffman et al. 2008). 
Besides the anemia, another important laboratory feature that indicates an accelerated 
hemolysis is reticulocytosis which is characterized by an increase in reticulocytes in 
peripheral blood (see Fig. 02). This increased prevalence of reticulocytes is the physiological 
bone marrow response attempting to the restoration (in number) of the cells loosen. In the 
absence of concomitant bone marrow disease, a brisk reticulocytosis should be observed 
within three to five days after a decline in hemoglobin. After this period, in a normal 
condition the RBCs production is compensated, leading to a normal and stable hemoglobin 
concentration.  
In contrast, in the hemolytic anemia, although a marked reticulocytosis is observed after the 
RBCs destruction, the bone marrow is not able in compensate the formation of normal RBCs. 
The main cause for this fail is the fact that the primary event affecting RBCs involves an 
absence, reduction or malformation of hemoglobin. In the next sections we will discuss two 
important erythroid diseases that culminate to chronic hemolytic anemias whose main 
genetic alteration is accounted by a point mutation: the sickle cell disease and Thal. We will 
also discuss another important disorder generated by a point mutation that importantly has 
beneficial effects on the described diseases: the Hereditary Persistence of Fetal Hemoglobin.   
4. Sickle Cell Disease 
Sickle cell disease (SCD) is a worldwide health problem and one of the most common 
inherited disorders firstly reported in America by James Herrick in 1910. In 1949, Linus 
Pauling and colleagues demonstrated that sickle hemoglobin had a different migration 
compared to the normal hemoglobin in an electrophoretic field and recognized that this 
disease must be associated with a variant hemoglobin molecule (Pauling et al. 1949) The 
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genetic alteration that leads to this autosomal recessive inherited disorder was described in 
1957 by Ingram and colleagues, as a missense mutation (A – T) that introduces a substitution 
of a glutamic acid, a polar negatively charged aminoacid (in hemoglobin A) to valine, non 
polar aminoacid (in hemoglobin S) at position 6 of the globin -chain causing an impairment 
in hemoglobin structure and function (Ingram 1957). 
Since SCD has a Mendelian segregation, individuals can be homozygous or heterozygous. 
The genetic diagnostic of the disease can identify an important prognostic in the 
homozygous for the sickle gene (SS) once their erythrocytes contain at least 90% hemoglobin 
S. Those who are heterozygous (AS) have sickle cell trait and their erythrocytes contain both 
hemoglobin A (about 50-60%) and hemoglobin S (about 30-40%). Sickle cell trait is a clinical 
state that is clinically benign except under conditions of severe acidosis or low partial 
oxygen pressure (Pace 2007). 
An important piece of information about the prognostic of patients carrying SCD was 
described by several studies that identified single nucleotide polymorphism (SNPs) in the  
globin locus. These haplotypes were firstly defined in African population and identified in 
different regions that could be linked to different gene mutations. These regions are Benin, 
Senegal, Central African Republic (Bantu) and Cameroon. Another important haplotype was 
described in Saudi Arabia and India. The identification of these haplotypes was possible by 
digesting the  globin locus with several restriction enzymes. The pattern of each haplotype 
can be seen in Fig. 05. The occurrence of these is very broad worldwide but mainly in 
America, what is a direct consequence of the forced migration of Africans to America as 
slavers. The identification of these haplotypes is a very important tool for evaluating the 
prognostic of the disease, since several studies showed that different haplotypes accounts 
for different clinical evolution of the disease. For example, the Bantu haplotype is associated 
with a worse prognostic than others in the majority of cases (Pagnier et al. 1984; Nagel et al. 
1985; Pace 2007). 
 
Fig. 5. Different haplotypes found in association with Sickle Cell Disease (SCD). Using 
different restriction enzymes, several haplotypes could be found and associated with the 
better or worse prognostic in SCD. 
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A significant association between endemic regions of malaria infestation and spontaneous  
globin mutation were described by Carlson et al based on natural selection, since people 
with sickle cell trait are more resistant to malaria than people with two normal  globin 
genes. This is a very elegant example of a point mutation as a factor eliciting a direct 
consequence in the adaptation of a pathogen to the host (Carlson et al. 1994). 
Under oxygenated conditions both hemoglobin S and hemoglobin A have similar function. 
However, when hemoglobin is in the deoxygenated state, cells carrying hemoglobin S 
become deformed and acquire sickle shape. The alterations observed in the HbS cell 
morphology is due the appearance of a new hydrophobic site in hemoglobin S that interact 
with another HbS protein leading to a formation of a long and multi-stranded fibers. This 
leads to several alterations such as red cell membrane damage, chronic hemolysis, altered 
interactions between sickle red blood cells and vascular endothelial cells, and inflammatory 
responses from such interactions (Fig. 6) (Pace 2007; Hoffman et al. 2008). 
 
Fig. 6. Pathophysiology of sickle cell disease – The single point mutation (GAG – GTG) at  
globin gene leads to a formation of sickle hemoglobin(HbS). This alteration is caused by a 
change of a Glutamic acid by a Valine at position six of the protein (A). Under oxygenation 
state the HbS have the same function than a normal Hb, however at absence of oxygen these 
cells interact with other HbS cells forming a HbS polimer that adhere to blood vessels 
leading to several alterations observed in this disease (B). Figure was produced using 
Servier Medical Art, http://www.servier.co.uk/medical-art-gallery/SlideKit.asp?kit=18.  
Another hallmark event caused by the alteration in red blood cells shape is the sequestration 
of blood cells in the spleen and liver, resulting in a preeminent hepatosplenomegaly 
typically observed in SCD patients. In a first moment, the bone marrow increases the 
production of reticulocytes. As a consequence, the level of these cells that normally 
represents about 1% can be as high as 10% under these conditions. With the continued 
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destruction of red blood cells associated to the hemolysis in the bloodstream, a great 
decrease in the number of circulating red blood cells can be observed culminating with  an 
anemic condition (Pace 2007). 
The primary event involved in the pathophysiology of SCD is the vaso-occlusion outcome 
that can promote strokes, resulting in tissues infarctation, painful episodes, acute chest 
syndromes and thrombosis of cerebral vessels (Shapiro et al. 1995). 
Several studies support the idea that exists a genetic predisposition to stroke associated with 
the different  globin haplotypes (Powars et al. 1994). The increase of sequenced data from 
Human Genome Project, associated with the improvement of bioinformatics tools and high-
throughput genotyping platforms and sequencing, called as the “genomic revolution”, 
accelerated the identification and association of SNPs with several diseases, including SCD. 
The association of this information is a powerful tool in the discovery of new associations 
between novel haplotypes and SCD prognostic (Pace 2007). 
Red cell transfusion and therapy with the use of Hydroxyurea (HU) are methods used to 
prevent the complications of SCD. The use of HU, a chemotherapy agent largely used in the 
treatment of mieloproliferative disease, in the SCD treatment was first demonstrated by the 
Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH). This study showed that by 
the use of this pharmacological agent, the rate of painful episodes and the need for 
transfusions were decreased. Another important finding is the correlation of HU treatment 
and the increase of HbF. This point will be discussed later on in this chapter (Steinberg et al. 
2003). 
The only curative therapy for SCD is the hematopoietic stem cell transplantation, but this 
therapy has some important complications such as acute and late toxicities that need to be 
considered before its use. The evolution of the transplantation method with the possibility 
of alternate use of stem cell source such as cord blood could be improve the cure of this 
disease for a large number of individuals (Pace 2007).  
5. Thalassemia 
The thalassemia term was first used for anemia often found in Italian people and the Greek 
shores and nearby islands. Today the term is used to refer to inherited defects in the 
biosynthesis of globin chains (Hoffman et al. 2008; Cao et al. 2010). 
The thalassemias are a group of inherited disorders characterized by alterations in the 
synthesis of one or more globin chain subunits in the hemoglobin tetramer. The clinical 
features associated with thalassemia arise due to an imbalanced production of globin, which 
leads to ineffective erythropoiesis and consequently hemolytic anemia. Thalassemic 
individuals may be asymptomatic or the clinical manifestations can vary from a 
hypochromic and microcytic anemia to changes that become incompatible with life.  
These differences in clinical manifestations arise from defects of varying severity in primary 
biosynthesis and modulation inherited factors, such as increased synthesis of fetal globin 
subunits. In more severe forms of disease, iron overload can occurs as a consequence of 
either blood transfusions (which is used as palliative treatment) or alloimmunization and 
blood-borne infections (Thein 1998).  
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Thalassemias represent one of the most common group of genetic disorders known, thus 
constituting a public health problem. Molecular analysis of these disorders, mainly the 
study of molecular changes underlying the thalassemia syndromes, has led to fundamental 
advances in understanding the structure and function of eukaryotic genes. The 
classification, pathophysiology and genetic basis of this disease were used as a model to 
understand the production and the formation of hemoglobin and their main function as 
carriers of oxygen molecules bounded to heme group.  
The thalassemia syndromes are named according to the globin chain whose synthesis is 
affected. Therefore, the -globin chains are absent or reduced in patients with -thalassemia, 
and -globin chain production is altered in patients with Thal, the  and  chains globin 
production are altered in patients with -thalassemia among others. This nomenclature is 
also important to subdivide the patients depending on the level of production of each globin 
chain, which can be reduced (eg  or +- thalassemia) or absent (eg  or  0- thalassemia). In 
this topic we will focus on Thal (Hoffman et al. 2008).  
Heterozygote individuals for  thalassemia, called thalassemia trait, may develop anemia, 
yet can have a normal life. Whereas individuals who are homozygous can be classified into 
different groups: (i) thalassemia intermedia - in which individuals has moderate anemia due 
to reduced production of -globin, and (ii) thalassemia major or Cooley's anemia - 
characterized by severe reduction or absence of production of -globin. These patients with 
Thal major are dependent on periodic blood transfusions and as a consequence of this 
procedure, they may have a significant accumulation of iron in multiple organs and tissues. 
Thus, the treatment with iron chelating drugs, such as deferoxamine is mandatory, and can 
also cause death. Currently the only curative treatment available for these patients is bone 
marrow transplantation (Wheatherall et al. 2001). 
5.1 Beta talassemia 
Strikingly, more than two hundred mutations have been described to date as associated 
with this disease. Total gene deletion which could account for the total absence of  chain 
synthesis is rarely observed in Thal. The majority of the mutations found so far are mainly 
either single nucleotide substitutions and  deletions or insertions of nucleotides on 
frameshift leading. Although there are several mutations described, only about nine of them 
usually represent more than 90% of cases of Thal in a particular ethnic group or region. 
Mutations can be divided into those that affect the transcription of mRNA (mutation on the 
promoter region and termination codon), those affecting mRNA processing (splicing 
junctions mutations, new signs of splicing, cleavage and recombination deficient) and those 
affecting the translation (Cao et al. 2011).  
As we discussed before, different types and amounts of human hemoglobin are determined by 
the selective expression of specific genes encoding each globin chain. Also encoded within the 
genes are the signals that permit the enzymatic machinery within the nucleus to excise 
precisely the introns from the mRNA precursor and bring together the exons to form a mature 
mRNA. Many mutations are related to transcription of the  globin genes. These mutations 
alter the promoter region upstream of the -globin mRNA coding sequence. In addition, other 
mutations can alter the sequence used for signaling the addition of the tail poly (A) of mRNA 
upstream of the  globin mRNA coding sequence. These events ultimately affects the mRNA 
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synthesis resulting in abnormal division and polyadenylation of mRNA precursor leading to 
reduction of mature mRNA (Table 1 and fig. 7) (Hoffman et al. 2008).  
 
             
       DEFECT 
 
TYPE OF THALASSEMIA 
mRNA non-functional  
1. Premature Finish Codon 
a. CD 15 G→A,   
b. CD 17 A→T,   
c. CD 35 C→A,   
d. CD 39 C→T,   
e. CD 43 G→T,    
f. CD 121 A→T 
 
 
 0 
2. Short Deletion Shift Base (frameshift) 
a. CD 5 -CT,   
b. CD 6 -C,  
c. CD 8/9 +G,  
d. CD 16 -C ,  
e. CD 35 -C,  
f. CD 41/42 -TTCT,  
g. CD 76 -C,   
h. CD 109/110 1nt del 
 
 
 
0 
3. Mutation of the Start Codon ATG 
a. ATG→AGG,   
b. ATG→ACG 
 
0 
Abnormal Processing RNA 
1. Mutations Inside Introns 
a. IVS-1 nt 110 G→A,   
b. IVS-2 nt  705 T→G,  
c.  IVS-2  745 C→G  
d. IVS-1 nt 116 T→G,   
e. IVS-2 nt 654 C→T 
 
 
+ 
2. Activation of Cryptic Sites of Splicing 
a. CD 19 A→G,   
b. CD 26 G→A,   
c. CD 27 C→T 
 +* 
3. Mutations in exon-intron limits 
a. IVS-1 nt 1 G→A,  
b. IVS-1 nt 1  G→T,   
c. IVS-1 nt 2 T→G,   
d. IVS-2 nt 849 A→G,  
e. IVS-2 nt 849 A→C 
f. IVS-1 nt 5 C→G,   
g. IVS-1 nt 5 G→T,  
h. IVS-1 nt 128 T→G,  
i. IVS-2 nt 843 T→G  
 
0 
 
 
 
 
+ 
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       DEFECT 
 
TYPE OF THALASSEMIA 
Mutations in the promoter region 
4.  Reduction in the mRNA transcription  
a. -101 C→T,   
b. -92 C→T,   
c. -88 C→T,   
d. -31 A→G,   
e. -30 T→A,   
f. -28 A→C 
 
 
 
+ 
Mutations in polyadenylation site mRNA (AATAAA) 
a. AACAAA,   
b. AATAAG,   
c. AATGAA,    
d. AATAGA,   
e. A (del AATAA) 
 
 
+ 
Structural Mutations (elongated chains or hyperunstable)   
a. CD 49 +TG (Hb Agnana),  
b. CD 110 TC (Hb Showa- Yakushiji),  
c. CD 114 -CT +G (Hb Genebra) 
+ 
Table 1. Frequent examples of point mutations causing thalassemias in humam population, 
according to their location in the molecule, the functional defect associated and the 
consequence on globin synthesis. 
 
Fig. 7. Different types of point mutation involved in the development of Thal – Point 
mutations can alter the start of translation, RNA capping, the frameshift of protein 
translation and the RNA stability. The creation of a stop codon, as in the CD39 type of 
Thal, is responsible by a formation of a non-functional protein that is degraded causing 0 
thalassemia. 
Specifically in the splicing process, which is necessary the recognition of specific sequences 
by the spliceosome in the intronic region, point mutations are responsible by the impaired 
globin production. In fact, various forms of Thal are caused by mutations that either 
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damage the process of splicing of the mRNA precursor to mature mRNA in the nucleus or 
block translation of mRNA in the cytoplasm.  
Some point mutations change the dinucleotide (GT) or (AG), which are extremely important 
in the exon-intron junctions on the conventional processing, completely block the 
production of mature RNA. Therefore, the -globin molecules are not produced, leading to 
the appearance of a 0 thalassemia.  
Other mutations can change the consensus sequences surrounding the invariant 
dinucleotide AG and GT. This consequently decreases the efficiency of conventional splicing 
which shall occur at a level between 70% and 95%, resulting in  + talassemia. Another 
mechanism of change is the result of splicing mutations that do not occur close to any 
normal splice site. Such changes could occur in a region located in intron region which is 
crucial for regular splicing of the gene, called crypt splice sites. They resemble the consensus 
sequences of local splice, but usually do not support splicing . The mutations are able to 
activate these sites through the alteration to GT or AG site, generating a consensus sequence 
that stimulate the splicing machinery (Fig. 8) (Hoffman et al. 2008). 
There may be mutations that suppres the translation in several regions along the mRNA, 
and it is a common cause of thalassemia. The most common form of thalassemia in 
people of the region of Sardinia (Italy) is the result of a base substitution, which changes the 
codon encoding the amino acid 39 of the  globin gene (CAG-TAG), whose sequence 
equivalent (UAG) characterizes the termination of translation of the mRNA, forming a 
premature stop codon that prevents the ability of mRNA to be translated into normal -
globin. This phenomenon can also result in frameshift mutations causing small deletions or 
insertions of a few bases, or multiples of 3, which alter the sequence of nucleotides that is 
read during translation (see Fig. 7). 
Two groups of partial deletions of the  gene are known: (i) loss of 600 bases before the start 
of the gene, including the exon 1, intron 1 and part of exon 2, and (ii) loss of 619 nucleotides 
at the end of  gene. In both cases, the synthesis of  chain does not occur. This type of Thal 
is common in northwestern India and on Pakistan (Khan et al. 1998; Madan et al. 1998). 
A study in Turkey aiming  to determine the origin of some of the mutations related to Thal 
identified twelve haplotypes, demonstrating a remarkable level of heterogeneity. From 22 
analyzed mutations in the -globin gene, 18 were related to a single sequence haplotype. 
This simple association encouraged an attempt to determine the origin of these mutations by 
comparing their frequencies in Turkey with other countries and / or the worldwide 
distribution of haplotype carrying them. However, the presence of several exceptions to 
"one haplotype / one mutation" cluster showed that the -globin gene is not static. Each of 
the mutations - IVS-I-10 (G -> A), Cd 39 (C -> T), IVS-I-6 (T -> C) and -30 (T -> A) - in the  
globin was associated with a minimum of two sequences of haplotypes. This fact can be 
explained by the potential existence of recombination mechanisms which are continuously 
activated (Bilgen et al. 2011). 
Some genetic factors may reduce phenotypic effects of some cases of Thal. A mechanism 
that exerts positive effects on Thal phenotypic traits is the decrease of the unbalanced 
production of the globin chains making the precipitation of these chains lower. 
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Fig. 8. Point mutations in the splicing sites are  responsible for the formation of a non-
functional  hemoglobin – The introduction of point mutations in the splicing sites at  intronic 
regions can create a new splicing site (highlighted in black) that can alter the structure of the 
 globin through the retention of a portion of intron forming an non-functional globin 
polypeptide. 
This feature leads to reduced production of  chains thus reducing the overall imbalance of 
 and  chains. The persistence in the production of  globin also acts reducing the 
imbalance between the globin chains. This persistence of HbF production relies on the 
transmission co-genetic factors. Hereditary persistence of fetal hemoglobin (HPFH) in adults 
can be present in two forms according to the distribution of HbF within red blood cells, i. e. 
homogeneous or heterogeneous distribution. The aspects of this disorder will be discussed 
in the next section below. 
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6. Hereditary persistence of fetal hemoglobin  
The hereditary persistence of fetal hemoglobin (HPFH) is a group of genetic disorders 
characterized by continued expression of fetal hemoglobin (HbF) in adulthood. HPFH could 
be divided in (i) pancellular with homogeneus distribution of HbF among all red cells and 
(ii) heterocellular with an increase in HbF in some cells called F cells (Pace 2007). 
On a molecular point of view, pancellular HPFH is in the most of cases caused by extensive 
deletions in the group , called deletional HPFH (dHPFH). Point mutations in the promoter 
region of both  globin genes, called non-deletional HPFH (ndHPFH) are found in the most 
of cases diagnosed as heterocellular HPFH (Hoffman et al. 2008).  
6.1 Deletional HPFH 
The increase in HbF caused by dHPFH is associated with deletions in DNA sequences in the 
 globin cluster, with the preservation of the A and G globin gene. Heterozygous 
individuals for delecional HPFH have an increase in the HbF up to 20% to 30% of total 
hemoglobin in the erythrocytes with homogeneous distribution (pancellular).  
The mechanism responsible for the increase in HbF in dHPFH has not been completely 
elucidated. Some hypotheses have been proposed to explain these mechanisms and the more 
accepted  one is that the deletion removes competitive regions of  globin gene like the  and  
globin genes that under normal conditions would interact with the LCR, silencing the  globin 
expression and starting the HbA production. Together with the deletion of these genes, the 
removal of the silencer elements located in the region between genes A and  globin helps in 
the increment of HbF observed in this hematological disorder (Pace 2007; Ngo et al. 2011).  
To date, six different types of dHPFHs have been characterized: The HPFH-1 and HPFH-2 is 
characterized as a large deletion of approximately 105 kb in DNA sequence of the  and  
globin gene region; in the HPFH-3 and HPFH-4 the deletions are shorter with 
approximately 50 kb of DNA sequence from  to  globin removed; HPFH-5 is the smaller 
deletion characterized by the  removal of approximately 3 kb upstream to  globin until  0.7 
kb downstream from the  globin gene. Finally HPFH-6 had similar deletions profiles 
observed in type 1 and 2 with the involvement of A globin gene deletion (Fig. 9) 
 
Fig. 9. The deletional form of HPFH – Position of deletions involved in the increase of fetal 
hemoglobin after the birth are shown in the  globin gene cluster.  
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6.2 Non delecional HPFH 
The non deletional HPFH is characterized by a point mutation in the promoter region of the 
G globin gene or the A globin gene. In contrast to dHPFH there are several mutations 
involved in the increment of fetal globin in the ndHPFH that are clustered in three regions 
of the  gene promoters centered around positions -200, -175, and -115 of both A and G, 
relative to the transcriptional start site Some examples of ndHPFHs described in the 
literature are: Georgiana type (A -114 C-T), Greek type (A -117 G-A); African type (A -175 
T-C), Brazilian type (A -195 C-G), Italian type (A -196 C-T), English type (A –198 T-C), 
African type (A –202 C-T), Switzerland type (G –110 A-C), Algeria type (G –114 C-A), 
Japanese type (G –114 C-T), Australian type (G –114 C-G) Sardinian type (G –175 T-C) and 
African type (G – 202 C-G) (as summarized in (Pace 2007).  
The mechanisms involved in the reactivation of  globin were not completely understood for 
the most mutations described. It is suggested that these mutations interfere with the specific 
binding of some elements, mainly transcription factors, restricting or facilitating the 
connection of elements, suppressing the binding of transcription activators. 
Some studies support this hypothesis, since several authors identified many transcription 
factors that could interact with these regions which are able to activate the  globin 
promoter. In the ndHPFH English type, –198 T-C, the creation of a new site of interaction, 
CACCC box occurs which has high affinity for the transcription factor SP1 therefore 
increasing the strength of the A globin gene promoter (Ronchi et al. 1989; Fischer et al. 1990; 
Gumucio et al. 1991). This event allows the CACCC box interaction with the LCR, increasing 
the production of mRNA for  globin production. Besides SP1, Olave and colleagues 
identified in the same mutation (-198 T-C) another activator protein complex formed by 
DNMT1, CDC5-like protein, RAP74, SNEV and P52, that can bind to the promoter region of 
the A globin gene, also reactivating the expression of this gene (Olave et al. 2007). 
In the Greek type ndHPFH, the –117 G-A mutation deletes the repressor binding site of the 
transcription factor NF-E3, reducing its interaction with the globin gene promoter A 
allowing the interaction of CP-1, an activator of transcription (Mantovani et al. 1989). 
Mutations –175 T-C and –173 T-C prevents the formation of the protein complex containing 
GATA-1, OCT-1 and other transcriptional factors. It is suggested that this protein complex 
contributes to the formation of a repressive chromatin structure in the region -170 to -191  of 
the globin A promoter, leading to the silencing of this gene in erythrocytes. In addition, 
Magis and Martin hypothesized in 1995 that the transcription factor HMG1 binds in the 
region -175 of the A gene promoter and interacts with the GATA-1 (Magis et al. 1995). 
The -195 mutation, that characterize the ndHPFH Brazilian type, was identified by Costa 
and colleagues in 1990, through the study of a Caucasian patient bearer of hereditary 
spherocytosis and splenectomized, with HbF levels of 7% (13.9% of chains G and 86.1% of 
chains A). Two brothers of these individuals also had elevated HbF (4.5% and 4.7%) with 
predominance of the A chains, however, they were not suffering from spherocytosis (Costa 
et al. 1990). Analysis of DNA-protein interaction demonstrated that the increased synthesis 
of HbF, due to the –195 C-G mutation is not mediated by the protein and SP1 or a new site 
CACCC box creation (Takahashi et al. 2003). Thus, the mechanism of increased levels of 
HbF in patients with ndHPFH Brazilian type is different from the -198 mutation that occurs 
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in the ndHPFH English type. In order to evaluate if the -195 mutation is able to increase the 
HbF in vivo, Cunha and colleagues in 2009 developed an in vivo study in which the -195 
mutation was inserted into the  globin gene promoter at a  globin cluster cloned in a cosmid. 
This construction was inserted in a transgenic mouse and through RT-PCR and RNAse 
Protection Assay (RPA) the authors demonstrated that the -195 mutation, together with all the 
 globin cluster is enough to raise levels of HbF in all phases of development of transgenic 
mice. This observation was supported by an increase in  globin gene expression in yolk sac, 
fetal liver and other organs of these mice compared to expression in mice carrying the wild  
globin cluster. The results showed that the presence of the mutation -195 together with the 
entire   globin cluster is sufficient to develop the phenotype of ndHPFH-B in mice (da Cunha 
et al. 2009). Even with these detailed studies, the complete mechanism involved in the 
reactivation of the globin gene in the Brazilian type A ndHPFH is not elucidated.  
Understanding the mechanisms involved in these mutations may be important for the 
development of new therapies based on reactivation of  globin gene which can assist in the 
treatment of hemoglobinopathies. 
7. Expression of gamma globin and the regulation of severity of sickle cell 
disease and beta thalassemia 
As we discussed above, in SCD a point mutation leads to a structural alteration in  globin 
protein, that in absence of oxygen acquires the ability of  forming  long and multi-stranded 
fibers that alters the red blood cell shape increasing the destruction of these cells in spleen 
and liver and finally causing an important hemolytic anemia. In Thal, the point mutations 
or deletions observed in  globin gene are responsible for altering the production of  globin 
protein. In the most severe form of Thal, the  thalassemia major, there is no production of 
this protein. As a result, the  globin normally produces precipitates inside the red blood 
cells leading to an increased destruction of these cells causing hemolytic anemia, as also 
observed in SCD patients. In both cases, when a high expression of  globin is observed, the 
patient has  a very mild clinical disorder when compared to patients with a low expression 
of this protein. This better condition is due to the increment of production of fetal 
hemoglobin (HbF), as we have presented before as caused by the assembly of two  chains 
with 2  chains (22). The clinical benefit induced by the increase of HbF in SCD patients 
has been repeatedly demonstrated by several authors. In this disease, the beneficial effects of 
HbF is due to its interaction with the HbS polypeptide, that form an asymmetric hybrid 
hemoglobin, referred to as HbF/S (2S). This molecul directly affects the stability of the 
sickle hemoglobin polymer, preventing its deleterious alteration in cell morphology. 
Moreover, the premature destruction of sickle erythrocytes increases the number of cells 
where HbF concentration is high (Pace 2007). 
Several studies over the last 20 years attempted to identify pharmacological agents able to 
increase the HbF in these patients. Several compounds that broadly influence epigenetic 
modifications, including DNA methylation and histone deacetylation were  tested.  
In the beginning of 1990, the use of Hydroxyurea (HU) was proposed for the treatment of 
SCD patients. This compound was firstly synthesized in 1869 and is widely used as an 
antineoplastic drug mainly employed to traet myeloproliferative disorders. During the 90’s 
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several experiments were conducted mainly by the Multicenter Study of Hydroxyurea in 
Sickle Cell Anemia (MSH) and the results showed that HU were able to decrease the 
morbidity of SCA in adults, reducing the incidence of painful episodes and acute chest 
syndrome. These studies also revealed that this compound could be used to increase fetal 
hemoglobin (HbF) concentration therefore reducing the vaso-occlusive complications and 
diminishing hemolysis (Steinberg et al. 2003). The ability of HU in the generation of Nitric 
Oxide (NO) is reported as the main property which can partially explain the augment of  
globin production. In this sense, NO could act as a second messenger in a signaling cascade 
leading to the activation of several important genes. The results found in these first studies 
triggered other trials that used HU in Thal. Although the results were considered very 
promising, the augment of HbF in Thal was not observed in all patients (Lou et al. 2009). 
To date, HU is the most widely used drug for adult SCD patients and is also highly used in 
 thalassemia patients. Despite of several studies addressing this issue, the metabolic 
pathways and the set of genes expressed upon induction by HU are not completely known. 
Recently, some studies have evaluated patients and cultured cells before and after HU 
treatment in order to identify metabolic pathways and genes that could shed some light in 
the mechanism of action of this drug. In one of these studies conducted in 2006 by Costa et 
al, the mechanisms surrounding the in vivo action of HU were evaluated using a global 
gene expression analysis in cells obtained from the bone marrow of a SCD patient before 
and after HU treatment. The results suggested that HU induced significant changes in the 
gene expression pattern of SCD patient, mainly in global signal transduction pathways. 
This gene expression alteration may have a direct effect in the induction of globin genes 
and in genes associated with channel or pore class transporter. These pore transporter 
genes are thought to interfere in the hydratation status of cells, interfering with the 
rheological properties of them, what is very important in SCD (Costa et al. 2007). Having 
the same objectives and similar experimental design, another important study was 
conducted by Moreira et al (2007) using suppression subtractive hybridization (SSH) in 
HU-treated and -untreated reticulocytes of patients with SCD . In this report, similar 
pathways initially described by Costa were also identified after HU treatment. 
Additionally were also found some genes involved in chromatin modifications like 
SUDS3, FZD5 and PHC3. Although these studies have contributed to elucidate the 
transcriptional response influenced by HU, the molecular mechanisms involved in HU 
treatment remain unclear (Moreira et al. 2008). 
After the demonstration that some chemical agents are able to increase HbF concentration 
many efforts have been developed in order to find other inducers or a combination of agents 
able in ameliorate the symptoms of SCD and Thal. Several potential therapeutic agents and 
its combination have been investigated to use in these hemoglobinopathies. Table 2 shows 
some clinical trials used in Thal patients and their hematologic responses. 
Despite the clear beneficial effects observed after HU treatment, the use of this 
pharmacological agent is limited since long-term treatment has been associated with several 
deleterious effects. In order to diminish the HU treatment effects many efforts are made to 
find new therapeutic alternatives to treat SCD symptoms without side effects. Recently, dos 
Santos et al designed a new molecule by molecular hybridization combining portions of 
thalidomide and HU and tested as potential use in the oral treatment of sickle cell disease 
symptoms. The results showed that this molecule was able to increase the levels of NO 
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donor, as observed in HU treatment, and also demonstrated that different from what is 
observed in HU treatment, this new molecule had analgesic and anti-inflamatory properties, 
reducing the levels of tumor necrosis factor  (TNF ) thus representing an alternative 
approach to HU treatment (dos Santos et al. 2011). 
 
Terapeutic Agent Action Thalassemia 
Syndromes 
Increase in Total 
Hb (g/dl) (range) 
Responses 
5- Azacytidine Hypomethylation 
+/- cytotoxicity 
Thalassemia 
Intermedia 
2.5 [1.5 – 4] 1/1 
1/1 
3/3 
Hydroxyurea 
(HU) 
Cytotoxicity and 
erythroid regeration 
→high- F BFU- E 
HbE/ǃ- 
talassemia 
 
Thalassemia 
Intermedia 
HbE/ǃ- 
talassemia 
20 [1-3.3] 
27 [2.2 – 3.2] 
0.6 [0 – 1.7] 
1.0 
0.9 
3/3 
2/2 (ǃ globin) 
11/13 
3/8 
7/19 
 
Sodium 
Phenybutyrate 
(SPB) 
? HDACi effect Thalassemia 
Intermedia and 
Major 
2.1 [1.2 – 2.8] 4/8 untransfused 
Arginine Butyrate 
and AB+ 
Erithropoietin 
(EPO) 
Activates Ǆ globin 
gene promoter, (SSP 
binding),     (? 
HDACi effect) 
Thalassemia 
Intermedia and 
Major 
2.7 [0 .6 – 5] 7/10 (AB +/- EPO) 
Isobutyramide Activates Ǆ globin 
gene promoter 
Thalassemia 
Intermedia and 
Major 
Increase in HbF, 
Reduced 
Transfusion 
Requeriments 
6/10 
2/4 
EPO Stimulates Erythroid 
Proliferation, 
promotes erythroid 
cell survival 
Thalassemia 
Intermedia and 
Major 
2 [1 – 3] 
2.5 
2 
Reduced 
Transfusion 
Requeriments 
5 – 7/10 
4/4 
8/10 
3/26 
5/10 
Darbepoietin Stimulates 
Erythropoiesis 
Thalassemia 
Intermedia 
1.6 [0.7 – 3.8] 4/6 
HU+EPO As Above Thalassemia 
Intermedia 
HbE/ǃ- 
talassemia 
1.7 [0.5 – 4] 
1.2 
 
1/5 
HU+SPB As Above ǃ Lepore  3 [2 – 4] 2/2 
 
Table 2. Hematologic Responses to Fetal Globin Gene Inducers or Erithropoietin (EPO) in 
Thal Patients (Perrine 2005). 
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8. Molecular biology and the identification of targets to treat SCD and beta 
thalassemia diseases  
It has been a very well established concept the benefits in the increment of -globin levels in 
the treatment of patients SCD or Thal (Cao et al. 2011; Ngo et al. 2011). 
Therefore the development of new therapies targeting the increment of  globin production 
can become possible through the identification of the molecular mechanisms involved in 
fetal globin gene silencing and its reactivation which needs to be known in depth. An 
excellent model to study these mechanisms is the HPFH, a disorder in which the  globin 
production is not silenced, as described above. The mechanisms involved in the reactivation 
of  globin have been scrutinized in several studies. Olave et al. studied the proteins able to 
bind at the  globin promoter in the presence of a point mutation that leads to an English 
form of HPFH (–198TC). The results showed that a protein complex binds to this region 
and is able to increase the HbF production. The authors suggested that DNMT1 protein, one 
member of this putative complex, acts as a chromatin remodeling protein opening the 
chromatin and triggering the  globin expression (Olave et al. 2007). In another interesting 
study developed by Andrade et al., the pattern of gene expression was evaluated in 
reticulocytes of an individual with the deletional form of PHHF. In this study the authors 
also identified the up-regulation of chromatin remodeling proteins (ARID1B and TSPYL1 ) 
as also involved in the reactivation of  globin (de Andrade et al. 2006).  
Despite the studies with HPFH, several authors have described the interaction of genes with 
the activation or silencing of  globin promoter. Among these genes EKLF has been pointed 
out in numerous  reports as the main responsible for the regulation of  globin expression. 
The increase in the expression of this gene occurs in accordance with the increase of  globin 
producing and  globin silencing. The main function of this protein seems to be in the 
activation of another gene called BCL11A whose gene product is able to bind at  globin 
genes promoter repressing its transcription (Figure 10). The control of EKLF and BCL11A 
production could be further explored as a therapeutical strategy to increase the production 
of HbF and ameliorate hemoglobin disorders such as Thal and sickle cell disease (Sankaran 
et al. 2008; Xu et al. 2010; Jawaid et al. 2011; Wilber et al. 2011). 
Another important contribution aiming to clarify the understanding of -globin genes 
silencing is the results found in the analysis of the hematopoietic transcription factor GATA-
1. This gene, as we discussed before is a zinc finger protein that binds to WGATAR  
elements located mainly in the regulatory regions of  erythroid genes, including the   and  
globin genes (Weiss et al. 1995; Weiss et al. 1997).  
A direct interaction between GATA1 and -globin silencing was highlighted in two different 
studies. In the first one, the authors showed the importance of a 352-bp region harboring a 
conserved GATA element at position -566 5’of the HBG1 is required for -globin silencing in 
transgenic mice. In the second report, the authors correlated a mutation found in GATA site 
in the HBG2 gene with the increase in  globin expression in a family with HPFH. These 
results showed that GATA-1 can act as a repressor of  globin gene despite its widely 
described role in the literature as an activator of   and  globin genes. The mechanism 
whereby GATA-1 exerts these distinct functions remains unresolved. Some evidences  
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Fig. 10. EKLF levels coordinate the hemoglobin switching. The activation of globin genes  is 
dependent of the production of EKLF protein. A low level of EKLF is observed during the 
fetal stage. Since EKLF is essential for the activation of BCL11A, low levels of this gene is 
also reduced. The lowly expressed BCL11A is unable to repress Ǆ-globin genes and EKLF 
with the recruitment of the NFE4 and CP2, preferentially interacts with the Ǆ-globin 
promoters. This interaction stimulates the assembly of LCR elements activating the 
production of Ǆ-globin protein and consequently the HbF formation. In the adult stage, high 
levels of EKLF is observed. The increase of this protein promotes an overexpression of 
BCL11A ultimately repressing the Ǆ-globin genes under these circunstances. In this situation 
the EKLF binds preferentially to the ǃ-globin promoter activating the ǃ-globin gene with the 
recruitment of the LCR. This figure was adapted from  (Wilber et al. 2011). 
showed that this repression mechanisms could occurs via two other genes: FOG-1 and 
NuRD. FOG-1 is also a zinc finger protein that binds to GATA-1 acting as an important 
player in both activation and repression of genes modulated by GATA-1. FOG-1 interacts 
with several protein complexes, including NuRD (nucleosome remodeling and histone 
deacetylase), that is a co-repressor complex that interacts with several N-terminal motifs 
found in other transcriptional repressors, for instance, the BCL11A gene. In an experiment 
using transgenic mice bearing three different mutations that completely abrogate the 
binding between NuRD and FOG-1, the authors showed that animals homozygous for these 
mutations were  anemic and  displayed defects in platelet formation. These results indicate 
that this interaction is essential for normal erythroid and megakaryocyte development. The 
same authors concluded that the FOG-1/NuRD interaction is indispensable for the 
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expression of -globin gene and this interaction was not required for the repression of 
human -globin in vivo (Miccio et al. 2010; Xu et al. 2010).  
Despite several attempts, the complete molecular mechanism involved in the switching of 
globins and the reactivation of  globin remains to be elucidated. Is clear that chromatin 
remodeling in the  globin region is the main process whereby HbF reactivation occurs, once 
the expression of genes involved in this process are found in most of gene expression 
profiling studies using HPFH as a model. However, additional studies are necessary in 
order to identify a complete overview of metabolic pathways able to increase the HbF 
production and raise the possibility for the identification of new targets that could be used 
as therapeutical agents to treat SCD and Thal.  
9. Conclusion 
The mechanisms underlying the hemolytic anemia are very complex and the prognosis of 
this group of diseases is greatly influenced by the gain or loss-of function in key genes 
involved in the regulation of synthesis and destruction of globin proteins. Several molecular 
events can be linked to the alteration in gene function. In this chapter, we focused on point 
mutations interfering in the nature and the severity of SCD and Thal. The comprehension 
of the molecular basis and the identification of proteins involved in the onset and 
development of a disease can enable the development of drugs specially designed to 
targeted therapy. There are some well succeeded examples of the use of molecular biology 
to design drugs to treat a specific disease. One of the most classical examples comes from 
the study of another hematological disease: the Chronic Myeloid Leukemia (CML). The 
development of this CML is characterized by the expression of a BCR-ABL protein 
produced by a genetic translocation event. Using molecular biology approaches, the BCR-
ABL inhibitor imatinib was the first molecular targeted cancer therapy designed to bind 
inactive the translocated product of BCR-ABL protein. The employment of such molecular 
approach in the field of hemolytic anemias can open up new avenues of investigation taking 
advantage of the large scale studies to found new point mutation in genes involved in these 
diseases and correlate with the prognosis of each patient. Although many decades of efforts 
have been devoted to the mechanism elucidation of these diseases, much more remains to be 
done concerning to the identification of new point mutations conferring function on the 
disease progression,. In this context, the current scenery worldwide seen to be very prolific 
due to the recent large investments in  the genomic revolution of next generation sequencing 
approaches. These approachs can be easely  exploited through the large scale transcriptome 
(RNAseq) dissecation of hemolytic anemias. It may provide interesting links between the 
expressed genes by a specific disease, such as SCD and thal, and help in better 
understanding the association between the mutations and the metabolic pathways activated 
in each case. Thus the dissection of the involved metabolic pathways can identify key genes 
responsible for the disease development and progression. In addition, although important 
studies using molecular biology techniques highlighted the function of several genes 
involved in the hemolytic anemias, several questions are currently partially understood. For 
example, what are the transcriptome and proteome difference between patients that have 
the same mutations causing Thal but that have different phenotypes (major and 
intermedia)? The answer for this question is a promising strategy to identify new genes 
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involved in the severity of these  disease. Also, which are the genes that are modulated in 
each type of HPFH? The identification of these genes could help in the elaboration of new 
therapies to increase the fetal hemoglobin in SCD and Thal. Once the modulation and 
severity of these diseases is strictly correlated with mutations and haplotypes, this feature 
make them a very interesting and fruitful model for study of point mutation and genome 
plasticity using molecular biology approach seeking for further improvements for patients 
built on the field regenerative medicine and genetic therapy. 
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